Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC148 Monotherapy and Combinations in Advanced Solid Tumors
NCT06016062Phase 2Recruiting
- Sponsor
- RemeGen
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of RC148 Injection + pemetrexed disodium for injection + carboplatin injection in solid tumor, non-small cell lung cancer (NSCLC), Cervical Cancer (CC), gastric cancer (GC), lung adenocarcinoma, sponsored by RemeGen. Started Sep 2023; status: recruiting.
02
Drugs
RC148 Injection + pemetrexed disodium for injection + carboplatin injection
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)Cervical Cancer (CC)gastric cancer (GC)lung adenocarcinoma
Beyond the preview
Go deeper on NCT06016062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06016062.